| Literature DB >> 29021631 |
Adel R Moawad1,2,3, Maria C Fernandez1,2, Eleonora Scarlata1,2, Chandra Dodia4,5, Sheldon I Feinstein4,5, Aron B Fisher4,5, Cristian O'Flaherty6,7,8.
Abstract
Prdx6 -/- male mice are subfertile, and the deficiency or inactivation of Peroxiredoxins (PRDXs) is associated with human male infertility. We elucidate the impact of the lack of PRDX6 or inhibition of its calcium-independent phospholipase A2 (Ca2+-iPLA2) activity by MJ33 on fertilization competence of mouse spermatozoa. Sperm motility, viability, fertilization and blastocyst rates were lower in Prdx6 -/- spermatozoa than in C57BL/6J wild-type (WT) controls (p ≤ 0.05). MJ33 inhibited the PRDX6 Ca2+-iPLA2 activity and reduced these parameters in WT spermatozoa compared with controls (p ≤ 0.05). Levels of lipid peroxidation and of superoxide anion (O2•─) were higher in Prdx6 -/- than in WT spermatozoa (p ≤ 0.05). MJ33 increased the levels of lipid peroxidation and mitochondrial O2•─ production in treated versus non-treated WT spermatozoa. Acrosome reaction, binding to zona pellucida and fusion with the oolemma were lower in Prdx6 -/- capacitated spermatozoa than WT capacitated controls and lower in WT spermatozoa treated with the PRDX6 inhibitor. In conclusion, the inhibition of the PRDX6 Ca2+-iPLA2 activity promotes an oxidative stress affecting viability, motility, and the ability of mouse spermatozoa to fertilize oocytes. Thus, PRDX6 has a critical role in the protection of the mouse spermatozoon against oxidative stress to assure fertilizing competence.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29021631 PMCID: PMC5636886 DOI: 10.1038/s41598-017-13411-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
MJ33 inhibits the Ca2+-iPLA2 activity of PRDX6 in mouse spermatozoa.
|
|
|
|
|---|---|---|
|
| 0 | 0.026 ± 0.012a |
| 10 | 0.007 ± 0.021a | |
| 20 | ND | |
|
| 0 | 10.3 ± 0.20b |
| 10 | 1.3 ± 0.11c | |
| 20 | 1.3 ± 0.14c |
The Ca2+-iPLA2 activity was measured in homogenates of total spermatozoa from Prdx6 −/− or WT mice treated with MJ33. Data are presented as mean ± S.E.M. Different letters in the same column denote significant differences (n = 3; P ≤ 0.05). ND, none detected.
Defeciency of PRDX6 and/or inhibition of PRDX6 Ca2+-iPLA2 activity impair fertilization and preimplantation embryo development in mice.
| Mice | MJ33 (µM) | N Oocyte | Cleavage n (%) | Blastocyst n (%) |
|---|---|---|---|---|
|
| 0 | 53 | 7 (13.2 ± 0.3)a | 0 (0.0%)a |
| WT | 0 | 38 | 25 (65.9 ± 2.3)b | 8 (32.0 ± 0.7)b |
| 10 | 43 | 12 (27.9 ± 0.6)a,c | 2 (16.7 ± 0.3)c | |
| 20 | 41 | 7 (17.1 ± 1.2)a | 1 (14.3 ± 0.3)c | |
| CD1 | 0 | 73 | 58 (79.5 ± 2.1)b | 34 (58.6 ± 1.9)b |
| 10 | 63 | 35 (55.6 ± 2.8)b,d | 15 (42.9 ± 1.7)d | |
| 20 | 48 | 20 (41.7 ± 2.0)c,d | 8 (40.0 ± 0.8)d |
Cleavage (24 h pi) and blastocyst development (4 days pi) after IVF of ovulated CD1 oocytes with Prdx6 −/−, WT or CD1 spermatozoa treated with MJ33 during sperm capacitation. Data are presented as mean ± S.E.M. Different letters in the same column denote significant differences (n = 3; P ≤ 0.05).
Figure 1Deficiency of PRDX6 or inhibition of its Ca2+-iPLA2 activity negatively impacted pronuclear formation after IVF. Proportions of oocytes showing pronuclear formation at different times post-insemination (pi) with WT (treated or not with MJ33) and Prdx6 −/− spermatozoa. 20–30 inseminated oocytes were evaluated in each group and time point. Data are presented as means ± S.E.M. Different letters denote significant differences (n = 3; P ≤ 0.05).
Figure 2Lack of PRDX6 or inhibition of its Ca2+-iPLA2 activity reduced sperm motility and viability in WT and Prdx6 −/− mice. Percentages of total (A), progressive motility (B), and (C) viability in MJ33-treated WT and in Prdx6 −/− spermatozoa are presented as mean ± S.E.M. Different letters denote significant differences (n = 4–6; P ≤ 0.05).
Figure 3Lipid peroxidation levels are increased due to the absence of PRDX6 or the inhibition of its Ca2+-iPLA2 activity. BODIPY C11 mean fluorescence in MJ33-treated WT spermatozoa and in Prdx6 −/− spermatozoa. WT spermatozoa treated with FeSO4 (40 μM) were used as positive controls. Different letters indicate significant differences (n = 4–7; P ≤ 0.05).
Figure 4Levels of superoxide (O2 •−) were increased due to the absence of PRDX6 or the inhibition of its Ca2+-iPLA2 activity in spermatozoa. Percentage of MJ33-treated WT and of Prdx6 −/− spermatozoa with MitoSox red fluorescence (production O2 •−). WT spermatozoa incubated in the presence of 20 µM Antimycin were used as positive controls. Different letters indicate significant differences (n = 4–10; P ≤ 0.05).
Figure 5The absence of PRDX6 or the inhibition of its Ca2+-iPLA2 activity impaired the zona pellucida binding and fusion to the oolemma of Prdx6 −/− or WT spermatozoa. (A) number of spermatozoa/oocyte following IVF of zona intact MII-oocytes with Prdx6 −/− and MJ33-treated WT spermatozoa. (B) Percentage of fertilized oocytes using WT (treated or not with MJ33) or Prdx6 −/− capacitated spermatozoa after IVF with zona-free ovulated CD1 oocytes. Data are presented as means ± S.E.M. Different letters denote significant differences (n = 3; P ≤ 0.05).
Figure 6The absence of PRDX6 or the inhibition of its Ca2+-iPLA2 activity impaired acrosome reaction in capacitated spermatozoa. Percentage of acrosome reaction in WT (treated or not with MJ33) or Prdx6 −/− capacitated incubated with progesterone (acrosome reaction inducer). Data are presented as means ± S.E.M. Different letters denote significant differences (n = 3; P ≤ 0.05).